Related Experiment Video
Updated: Jun 30, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Systemic therapy of metastasizing renal cell carcinoma]
M Staehler1, N Haseke, K Zilinberg
1Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Klinikum Grosshadern, Marchioninistrasse 15, 81377 München, Deutschland. michael.staehler@med.uni-muenchen.de
Abstract:
Once surgical options have been exhausted, systemic therapy is indicated for metastasizing renal cell carcinoma. Until recently this was carried out using mainly immunotherapeutic concepts with unsatisfactory results. Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal. To date, four substances have been approved to control angiogenesis in the therapy of renal cell carcinoma: sunitinib, sorafenib, temsirolimus, as well as a combination of bevacizumab and interferon alpha. Other substances, such as everolimus, pazopanib and axitinib, are currently the subject of clinical trials. Initial data on tolerance and efficacy was presented at this years annual conference of the American Society of Clinical Oncology (ASCO). This article examines current therapy options and ASCO data and discusses future trends.
Insights
For metastasizing renal cell carcinoma, anti-angiogenesis drugs like sunitinib and sorafenib offer new systemic therapy options. Recent American Society of Clinical Oncology data shows promising efficacy and tolerance for these targeted treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) treatment has historically yielded unsatisfactory results with immunotherapy.
- Clear cell RCC's high vascularity suggests angiogenesis inhibition as a viable therapeutic target.
Purpose of the Study:
- To review current systemic therapy options for metastatic renal cell carcinoma.
- To examine recent data on angiogenesis inhibitors presented at the American Society of Clinical Oncology (ASCO) annual conference.
- To discuss future trends in renal cell carcinoma treatment.
Main Methods:
- Review of approved angiogenesis inhibitors for renal cell carcinoma.
- Analysis of initial tolerance and efficacy data from the ASCO annual conference.
- Discussion of ongoing clinical trials for novel agents.
Main Results:
- Four angiogenesis inhibitors are currently approved: sunitinib, sorafenib, temsirolimus, and bevacizumab with interferon alpha.
- Everolimus, pazopanib, and axitinib are under clinical investigation.
- Initial ASCO data provides insights into the tolerance and efficacy of these agents.
Conclusions:
- Angiogenesis inhibition represents a significant advancement in the systemic therapy of metastatic renal cell carcinoma.
- Emerging data from ASCO and ongoing trials will further shape treatment strategies.
- Targeted therapies offer improved outcomes compared to historical immunotherapeutic approaches.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistant Cancers